Prodotti competitors / Area HIV 3 febbraio 2025 European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
Prodotti competitors / Area HIV 19 dicembre 2024 CHMP Positive Opinion for Vocabria + Rekambys for Adolescents in EU
Prodotti competitors / Area HIV 29 maggio 2024 Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
Prodotti competitors / Area HIV 13 marzo 2024 ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
Prodotti competitors 19 ottobre 2023 ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
Prodotti competitors / Area HIV 19 maggio 2022 Long acting HIV - REKAMBYS & VOCABRIA - Pubblicazione in gazzetta ufficiale - Classe di rimborsabilità: H
Prodotti competitors / Area HIV 19 novembre 2021 UK: First long-acting injectables to treat HIV approved by the National Institute for Health and Care (NICE)
Prodotti competitors / Area HIV 28 ottobre 2021 HIV - EC Decision issued for Viiv's Vocabria/Rekambys injection initiation of LA treatment of HIV
